

## **Pharmacy Formulary Updates for December 2024**

To offer a pharmacy benefit that is clinically appropriate and cost effective, we constantly review how we cover prescription medications. Periodic adjustments are made to meet these goals. The changes below are reflected in our online Preferred Drug List.

## The following is a list of drugs that changed formulary status December 2024:

| Drug Name            | Tufts Health Public Plan Formulary |
|----------------------|------------------------------------|
|                      | Tufts Health RITogether            |
| Carbamazepine 200 mg | NC                                 |
| Crexont              | NC                                 |
| Femlyv               | NC                                 |
| Glimepiride 3 mg     | NC                                 |
| Lazcluze             | Brand;PA                           |
| Neffy                | NC;QL                              |
| Nemluvio             | NC;QL                              |
| Onyda XR             | NC                                 |
| Simlandi             | NC;QL                              |
| Sofdra               | NC;QL                              |
| Тгуvіо               | NC                                 |
| Vigafyde             | NC                                 |
| Voranigo             | Brand;PA                           |
| Winrevair            | Brand;PA;QL                        |
| Zepbound             | NC                                 |

MB: Medical Benefit

- QL: Quantity Limitation
- NC: Not covered

**PA:** Prior Authorization

Step Therapy

**MB/RX:** Drug can be dispensed through Medical Benefit or Prescription Benefit